Streetbeat News

VVOS

Vivos Therapeutics, Inc.

Industry

Medical - Devices

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Open

3.25

Mkt cap

19M

Volume

50K

High

3.33

P/E Ratio

-0.66

52-wk high

6.28

Low

3.10

Div yield

N/A

52-wk low

1.91

Vivos Therapeutics has announced that its flagship daytime-nighttime appliance will be tested in a clinical trial at Stanford Medicine. The protocol for the trial has been finalized and participant enrollment will begin in early 2024.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:38 am

During Friday's intraday session, several health care stocks experienced significant movements. Vaccinex, Akso Health Group, T2 Biosystems, Vigil Neuroscience, Adagene, and Orgenesis saw their stocks rise, while Novo Integrated Sciences, LumiraDx, Jin Medical International, Cano Health, Universe Pharmaceuticals, and Vivos Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 5:31 pm

Healthcare stocks showed significant movement in Friday's pre-market session. RVL Pharmaceuticals, Vaccinex, T2 Biosystems, Akso Health Group, Exagen, and Bone Biologics saw gains, while Freeline Therapeutics, Nanobiotix, Longeveron, Vivos Therapeutics, BioCardia, and Koninklijke Philips experienced losses.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 1:06 pm

Vivos Therapeutics has signed a distribution agreement with a Dubai-based sleep testing company to support its international expansion. The company expects to generate revenue from this collaboration starting in 2024.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 11:33 am

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included Acorda Therapeutics (ACOR), Vivos Therapeutics (VVOS), Pasithea Therapeutics (KTTA), Enveric Biosciences (ENVB), 60 Degrees (SXTP), and Esperion Therapeutics (ESPR). Losers included MaxCyte (MXCT), Heart Test Laboratories (HSCS), Senti Biosciences (SNTI), Accolade (ACCD), Elutia (ELUT), and PDS Biotechnology (PDSB).

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 9:31 pm

U.S. stocks traded mixed with the Dow Jones index falling over 50 points and the NASDAQ rising 0.77%. RPM International Inc reported better-than-expected Q1 results with sales growing 4.1% YoY to $2.01 billion. Pixelworks, Gaucho Group Holdings, and Vivos Therapeutics saw their shares rise after positive news. However, Kineta, A10 Networks, and Trinseo saw their shares drop due to negative news.

Portfolio Pulse from Lisa Levin

October 04, 2023 | 6:30 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Vivos Therapeutics (VVOS), Nuvalent (NUVL), Histogen (HSTO), MiNK Therapeutics (INKT), Brainstorm Cell (BCLI), and Gritstone Bio (GRTS) saw their shares rise, with VVOS leading the gainers with a 105.4% increase. On the other hand, Inhibikase Therapeutics (IKT), Protagenic Therapeutics (PTIX), Standard BioTools (LAB), Nuwellis (NUWE), Lipella Pharmaceuticals (LIPO), and MSP Recovery (LIFW) saw their shares fall, with IKT leading the losers with a 33.2% decrease.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 5:31 pm

The article lists the stocks that have gained and lost the most in Wednesday's mid-day session. Gaucho Group Holdings, Vivos Therapeutics, and Conduit Pharmaceuticals were among the top gainers, while Molekule Group, A10 Networks, and Inhibikase Therapeutics were among the top losers. Cal-Maine Foods shares fell by around 8% due to weaker-than-expected sales for its first quarter.

Portfolio Pulse from Lisa Levin

October 04, 2023 | 4:48 pm

U.S. stocks traded higher with the Nasdaq Composite gaining around 1% on Wednesday. The ISM services PMI fell to 53.6 in September. BranchOut Food Inc. (NASDAQ:BOF), Gaucho Group Holdings, Inc. (NASDAQ:VINO), and Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw their shares rise. However, Kineta, Inc. (NASDAQ:KA), A10 Networks, Inc. (NYSE:ATEN), and Trinseo PLC (NYSE:TSE) experienced a drop in their shares. Crude oil fell by 4%.

Portfolio Pulse from Lisa Levin

October 04, 2023 | 3:59 pm

Vivos Therapeutics Inc (NASDAQ:VVOS) has announced two strategic agreements with Ormco and On Demand Orthodontist to provide Spark Clear Aligners to its national network of providers. This is expected to create additional revenue opportunities and expand Vivos' product line. The collaboration will also facilitate pricing discounts for Vivos' providers and joint marketing and sales support. The company expects faster treatment times and improved clinical outcomes for patients using Vivos CARE devices with Spark Aligners.

Portfolio Pulse from Vandana Singh

October 04, 2023 | 2:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.